ES2154326T3 - Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol. - Google Patents

Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol.

Info

Publication number
ES2154326T3
ES2154326T3 ES95901915T ES95901915T ES2154326T3 ES 2154326 T3 ES2154326 T3 ES 2154326T3 ES 95901915 T ES95901915 T ES 95901915T ES 95901915 T ES95901915 T ES 95901915T ES 2154326 T3 ES2154326 T3 ES 2154326T3
Authority
ES
Spain
Prior art keywords
fibrinogen
isoxazoline
isoxazol
receiver antagonists
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95901915T
Other languages
English (en)
Inventor
John Wityak
Chu-Biao Xue
Thais Motria Sielecki-Dzurdz
Richard Eric Olson
William Frank Degrado
Gary Avonn Cain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of ES2154326T3 publication Critical patent/ES2154326T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE A LAS NUEVAS ISOXAZOLINAS E ISOXAZOLES, UTILES COMO ANTAGONISTA DEL COMPLEJO RECEPTOR DEL FIBRINOGENO TROMBOCITARIO DE LA GLICOPROTEINA IIB/IIIA, A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS, LOS PROCESOS PARA PREPARARLOS Y A LOS METODOS PARA UTILIZARLOS, POR SEPARADO O EN COMBINACION CON OTROS AGENTES TERAPEUTICOS, PARA LA INHIBICION DEL CONJUNTO DE TROMBOCITOS, COMO TROMBOLITICOS Y/O PARA EL TRATAMIENTO DE TRASTORNOS TROMBOEMBOLICOS.
ES95901915T 1993-11-24 1994-11-14 Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol. Expired - Lifetime ES2154326T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15759893A 1993-11-24 1993-11-24
US23296194A 1994-04-22 1994-04-22
US33792094A 1994-11-10 1994-11-10

Publications (1)

Publication Number Publication Date
ES2154326T3 true ES2154326T3 (es) 2001-04-01

Family

ID=27388036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95901915T Expired - Lifetime ES2154326T3 (es) 1993-11-24 1994-11-14 Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol.

Country Status (24)

Country Link
EP (2) EP0730590B1 (es)
JP (1) JPH09505590A (es)
KR (1) KR100359046B1 (es)
AT (1) ATE198748T1 (es)
AU (1) AU695853B2 (es)
BR (1) BR9408137A (es)
CA (1) CA2174838A1 (es)
CZ (1) CZ141996A3 (es)
DE (1) DE69426604T2 (es)
DK (1) DK0730590T3 (es)
ES (1) ES2154326T3 (es)
FI (1) FI962184A7 (es)
GR (1) GR3035610T3 (es)
HR (1) HRP940952A2 (es)
HU (1) HUT74690A (es)
IL (1) IL111721A (es)
NO (1) NO309768B1 (es)
NZ (1) NZ276633A (es)
PL (1) PL182303B1 (es)
PT (1) PT730590E (es)
RU (1) RU2149871C1 (es)
SK (1) SK66696A3 (es)
TW (1) TW483895B (es)
WO (1) WO1995014683A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
DE69633245T2 (de) 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
EP0858457A1 (de) * 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE69632548T2 (de) * 1995-12-21 2005-06-02 Bristol-Myers Squibb Pharma Co. ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
EP0939757A1 (en) * 1995-12-22 1999-09-08 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
JP2001527513A (ja) * 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
WO1997048395A1 (en) * 1996-06-19 1997-12-24 Du Pont Pharmaceuticals Company Iontophoretic delivery of integrin inhibitors
EP0922039A1 (en) * 1996-08-15 1999-06-16 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
WO1998008840A1 (en) * 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US5738647A (en) 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
US5797867A (en) 1996-09-27 1998-08-25 Becton Dickinson And Company Iontophoretic drug delivery system, including method for activating same for attachment to patient
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
HRP980291A2 (en) 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
KR20010013977A (ko) * 1997-06-19 2001-02-26 블레어 큐. 퍼거슨 중성 ｐ1 특이성 기를 갖는 인자 ｘａ의 억제제
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
ZA988735B (en) 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
ZA99168B (en) * 1998-01-16 2000-07-11 Du Pont Pharm Co Pharmaceutical formulations and processes for their preparation.
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
CA2333647A1 (en) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
EP1131306A2 (en) 1998-11-18 2001-09-12 Du Pont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
WO2000053168A2 (en) * 1999-03-11 2000-09-14 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP2002538226A (ja) * 1999-03-11 2002-11-12 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤およびアスピリン、組織プラスミノーゲンアクチベータ（ＴＰＡ）、ＧＰＩＩｂ／ＩＩＩａ拮抗剤、低分子量ヘパリンまたはヘパリンの組合せ使用による血栓症の治療
WO2000059902A2 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
JP4458240B2 (ja) 2001-11-26 2010-04-28 ジェネンテック インコーポレイテッド カテーテル組成物とその用途
RU2209070C1 (ru) * 2002-09-30 2003-07-27 Нестерук Владимир Викторович Способ получения лекарственного препарата для инъекций
EP1677783A2 (en) 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
CN101768129B (zh) 2004-03-05 2012-05-23 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物的制备中间体
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
ATE548359T1 (de) * 2004-06-17 2012-03-15 Infinity Discovery Inc Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern
CA2583267A1 (en) * 2004-10-12 2006-04-27 Amgen Inc. Novel b1 bradykinin receptor antagonists
EP1817306A1 (en) 2004-10-13 2007-08-15 Amgen, Inc Triazoles and their use as bradykinin b1 receptor antagonists
BRPI0617076B1 (pt) 2005-09-02 2021-07-06 Nissan Chemical Corporation Composto benzamida substituída por isoxazolina da fórmula (1) ou sal do mesmo; composto benzamida substituido por 4-hidroxiiminametila da fórmula (2) ou sal do mesmo; pesticida; agente agroquímico; parasiticida interno ou externo para mamíferos ou aves; inseticida ou acaricida
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
DK1984344T3 (da) 2005-12-29 2013-01-14 Lexicon Pharmaceuticals Inc Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008070353A2 (en) 2006-11-07 2008-06-12 Genentech, Inc. Tissue plasminogen activator variant uses
KR101675607B1 (ko) 2009-04-07 2016-11-11 에머리티 파마 아베 치료제로서 이소옥사졸-3(2ｈ)-온 유사체
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP4105208A1 (en) 2013-07-31 2022-12-21 Novartis AG 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
EP4509511A1 (en) 2023-08-17 2025-02-19 Bayer Aktiengesellschaft Substituted spiro-isoxazolinyl lactams, salts thereof and their use as herbicidally active substances
CN117820143A (zh) * 2023-12-29 2024-04-05 上海应用技术大学 以kaiso蛋白为靶点的二苯醚类化合物及制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
HUT68769A (en) * 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JP3240534B2 (ja) * 1992-06-05 2001-12-17 コニカ株式会社 画像形成方法

Also Published As

Publication number Publication date
CA2174838A1 (en) 1995-06-01
DE69426604D1 (de) 2001-02-22
NO962096L (no) 1996-05-23
HU9601414D0 (en) 1996-07-29
NO962096D0 (no) 1996-05-23
EP0730590A1 (en) 1996-09-11
HUT74690A (en) 1997-01-28
KR960705794A (ko) 1996-11-08
HRP940952A2 (en) 1997-04-30
GR3035610T3 (en) 2001-06-29
DK0730590T3 (da) 2001-03-19
JPH09505590A (ja) 1997-06-03
WO1995014683A1 (en) 1995-06-01
FI962184L (fi) 1996-05-23
PL314591A1 (en) 1996-09-16
CZ141996A3 (en) 1996-11-13
ATE198748T1 (de) 2001-02-15
TW483895B (en) 2002-04-21
IL111721A (en) 2000-06-01
EP0970950A2 (en) 2000-01-12
SK66696A3 (en) 1996-11-06
PT730590E (pt) 2001-05-31
RU2149871C1 (ru) 2000-05-27
AU695853B2 (en) 1998-08-27
FI962184A0 (fi) 1996-05-23
EP0970950A3 (en) 2000-04-05
EP0730590B1 (en) 2001-01-17
FI962184A7 (fi) 1996-05-23
DE69426604T2 (de) 2001-05-10
PL182303B1 (en) 2001-12-31
IL111721A0 (en) 1995-01-24
NZ276633A (en) 1998-04-27
BR9408137A (pt) 1997-08-12
AU1098095A (en) 1995-06-13
NO309768B1 (no) 2001-03-26
KR100359046B1 (ko) 2003-08-02

Similar Documents

Publication Publication Date Title
ES2154326T3 (es) Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol.
EE9700312A (et) Fibrinogeenretseptori uudsed isoksasoliin- ja isoksasoolantagonistid
DK0730589T3 (da) Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister
ES2165441T3 (es) Inhibidores de calpaina y/o catepsina b oxazolidin sustituidos.
CL2004000119A1 (es) Composicion farmaceutica que comprende un agonista/antagonista de estrogenos definido y un secretagogo de la hormona del crecimiento, util para tratar una condicion que se presenta con una masa osea reducida.
ES2189824T3 (es) Antagonistas no peptidicos del receptor de taquiquininas.
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
ES2194265T3 (es) Derivados de piperidino 4-carboxamida y su utilizacion como antagonistas de la neuroquinina.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
HN1998000157A (es) Agonistas de prostaglandinas
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
ES2067874T3 (es) Derivados de acetamida.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
CL2004000524A1 (es) Mezcla herbicida que comprende picolinafeno (n-(4-fluorofenil)-6-[3(trifluorometil)fenoxi]-2-piridin carboxamida), un herbicida triazolo [1,5-c] pirimidina y opcionalmente un antidoto; composicion herbicida; proceso de preparacion de la composicion y
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
ES2156889T3 (es) Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos.
ES2138976T3 (es) Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
PA8495201A1 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
ES2171531T3 (es) Derivados de carbamoilmetilurea.
PA8505601A1 (es) Profarmacos de higromicina a
DOU2000000115U (es) Sistema indicador de uso dependiente para articulos absorbentes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730590

Country of ref document: ES